600725-41-5

Upstream product

• 600725-40-4 3-(3,4-diethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl)-piperidin-1-carbonyl]-amino}-propionic acid methylester 

Downstream Products

• 600724-73-0 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid {2-(3,4-diethyl-phenyl)-1-[1-(1-methyl-piperidin-4-ylmethyl)-1H-benzimidazol-2-yl]-ethyl}-amide 
• 600724-70-7 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid {2-(3,4-diethyl-phenyl)-1-[1-(4-dimethylamino-butyl)-1H-benzimidazol-2-yl]-ethyl}-amide 
• 600724-71-8 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid {2-(3,4-diethyl-phenyl)-1-[1-(1-methyl-piperidin-4-yl)-1H-benzimidazol-2-yl]-ethyl}-amide 

Relevant academic research and scientific papers

SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT

The invention relates to CGRP antagonists of general formula (I), in which A, X, Y, Z and R1 to R 3 are as defined in claim 1, the tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, hydrates of the salts, in particular

Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

The present invention relates to substituted piperidines of general formula wherein R, R2 to R5, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.